Press Releases

29 Jun 2017

EFPIA, EBE and Vaccines Europe Back EU Leadership in Sustainable, Collaborative Fight Against AMR

The launch of the European Commission’s Action Plan on Antimicrobial Resistance (AMR) confirms the EU’s determination to take a leading role in combatting this phenomenon, by proposing concrete and innovative solutions to benefit patients worldwide....

Read more
02 Jun 2017

Reinventing the European Advanced Therapies Sector: An Interview with Eduardo Bravo

In this interview with Eduardo Bravo, CEO of TiGenix and President of the Board of the European Biopharmaceutical Enterprises (EBE), we discuss the increasing challenge for EU biotech companies to commercialise at home, and the accelerating departure of cutting-edge European biotech start-ups through IPOs and, increasingly, mergers and acquisitions. Interview by Duane Schulthess/Vitaltransformation.com...

Read more
26 Apr 2017

Intellectual Property: the key to innovation and survival for small and medium-sized biopharma companies

Today is World Intellectual Property day, an opportunity to reflect on the relevance of intellectual property rights to society where invention and innovation is valued for the greater benefit of all. ...

Read more
09 Mar 2017

EBE, EFPIA and IFPMA have today launched a position paper entitled “Considerations for physicians on switching decisions regarding biosimilars”

Switching describes a physician's decision to exchange one product that a patient receives for another. With the introduction of biosimilars, physicians may be encouraged to switch patients from an original biologic (reference product) to any of its biosimilars (or vice versa) in order to reduce costs. ...

Read more
16 Feb 2017

EBE and EFPIA support ARM Initiative on Hospital Exemptions and Call for Increased Transparency on All Advanced Cell, Gene and Tissue Therapies

Brussels, 16 February 2017 - The European Biopharmaceutical Enterprises (EBE) and the European Federation of Pharmaceutical Industries and Associations (EFPIA) today express their support for...

Read more
19 Oct 2016

EFPIA and EBE Welcome NOR-SWITCH Results as a Valuable Step Forward

EFPIA and EBE welcome the results of the NOR-SWITCH study on biosimilar switching* and acknowledge its preliminary results as a step in the right direction of robust data generation that continues to enhance physician and patient confidence in using biosimilars. EFPIA and EBE also welcome the effort of the Norwegian authorities and investigators to initiate and carry out the NOR-SWITCH study....

Read more
19 Sep 2016

The European biotech ecosystem: EBE position paper recommends how to make funding go further

Brussels, 19 September 2016 The European Biopharmaceutical Enterprises (EBE) today published a White Paper that scrutinises funding available for innovative biopharmaceutical entrepreneurs in Europe and explores why fewer successful businesses are built in Europe – despite our exceptional science – than in other world regions....

Read more
18 Jun 2016

EBE Webinar: “Maintaining Europe’s Lead In Regenerative Medicine – New Approaches and Programmes”

Webinar - 1 July 2016 - 11.45-12.30 CET While the EU has had a global lead in ATMP technologies and regulation policy, other countries are moving aggressively into the space. The Japanese "Sakigake" accelerated pathway for regenerative medicines, as well as initiatives such as the UK's EAMs and EMA's PRIME are such examples. What are the National Governments and European Commission doing specifically to ensure that ATMP technologies are continued to be developed and commercialised in Europe?...

Read more
17 Jun 2016

Compromise Agreement on IVDs is a Solid Step in the Right Direction to enable Personalised Medicine

Brussels, 17 June 2016: The European Biopharmaceutical Enterprises, EBE, and the European Federation of Pharmaceutical Industries and Associations, EFPIA, welcome the agreement reached between the Council of Ministers and the European Parliament Health Committee (ENVI) on the adoption of the Regulation on In-Vitro Diagnostic (IVD) Medical Devices. This Regulation, adopted alongside the Regulation on Medical Devices, will ensure the increased safety of IVD medical devices and will allow patients to benefit from innovative healthcare solutions in a timely manner....

Read more
16 Jun 2016

EBE, the European Biopharmaceutical Trade Association, Unveils Its Leadership 2016-2018

(16 June 2016 – Brussels, Belgium): The European Biopharmaceutical Enterprises, EBE, is pleased to announce its Board of Directors for the term 2016-2018, following the decisions taken at the EBE and EFPIA (European Federation of Pharmaceutical Industries and Associations) Annual Meetings on 14 to 16 June 2016....

Read more
1 2 3